This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).
   
The BioHealx implant is a small coil made of a material that is absorbed by the body over time. It has been designed to close the fistula. As the fistula heals, the implant gradually dissolves from the body.
   

 This clinical trial is for men and women with HR+/HER2− stage II or III eBC patients treated with the study drugs, i.e., Kisqali® (ribociclib) + endocrine therapy (ET), or Verzenio® (abemaciclib) + ET, as per local label in routine clinical care settings.
   
The purpose of this study to learn more about how people with early breast cancer feel and respond when treated with either Kisqali® (ribociclib) plus ET or Verzenio® (abemaciclib) plus ET treatment.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM.
   

This research study is being conducted to better understand how the Eye90 radiation treatment affects liver tumors.

After a patient undergoes transplant surgery, the removed liver tissue will be examined using detailed imaging and microscope techniques to study how well the treatment worked and how the radiation particles were distributed in the tumor.

No additional tests, procedures, or visits are required for participation in this study.

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).

This trial compares the effect of two different types of coaching for people living with Rheumatoid Arthritis (RA). Living with RA is difficult, and some people will also experience challenges with stress, anxiety, and difficult emotions (depressive or sad symptoms).

This research study is being done to learn more about the study drug 68Ga-PSMA-11. The study drug is composed of a radioactive substance called gallium-68 (68Ga) combined with a substance that attaches to a protein called PSMA (Prostate-Specific Membrane Antigen), which is found in large amounts on prostate cancer cells. 68Ga-PSMA-11 combined with CT or MRI may help regular doctors see where possible prostate cancer lesions are, even in places that regular scans like MRI might miss.

The main purpose of this study is to investigate whether the study drug, trontinemab, is able to slow down the worsening of symptoms in participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. 

Trontinemab combines an anti-amyloid antibody with a module that helps deliver the antibody more efficiently to the brain. Once in the brain, trontinemab works by removing amyloid-beta plaques, a protein associated with Alzheimer’s disease.